# Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285

> **NCT00243568** · PHASE3 · WITHDRAWN · sponsor: **Merck Sharp & Dohme LLC**

## Conditions studied

- HIV Infections
- Acquired Immunodeficiency Syndrome

## Interventions

- **DRUG:** Vicriviroc

## Key facts

- **NCT ID:** NCT00243568
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2005-09-01
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2019-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00243568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00243568, "Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00243568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*